Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1

We are pleased to have completed enrollment in the ILLUMINATE-C Phase 3 study, said Pritesh J. Gandhi, PharmD., Vice President and General Manager, Lumasiran Program at Alnylam.